MB49-luc Orthotopic Mouse Model Service for Bladder Cancer

The MB49-luc orthotopic mouse model integrates stable firefly luciferase expression with anatomically faithful bladder tumor engraftment, offering researchers a quantifiable, longitudinal window into tumor establishment, expansion, and therapeutic response within an immunocompetent syngeneic setting. Alfa Cytology delivers this traceable platform with calibrated imaging workflows, standardized luciferin administration protocols, and rigorous signal-validation criteria, ensuring reproducible photon flux quantification from pilot feasibility through terminal pharmacodynamic analysis.

Overview of MB49-luc Orthotopic Mouse Model for Bladder Cancer

MB49-luc is a genetically engineered derivative of the parental MB49 murine bladder carcinoma line, generated through stable transfection with a firefly luciferase reporter construct—most commonly via lentiviral vectors encoding Photinus pyralis luciferase or pSELECT-zeo-LucSh plasmid systems. The resulting cells retain the full tumorigenicity and epithelial phenotype of the parental line while emitting a robust, ATP-dependent bioluminescent signal upon substrate exposure. When instilled orthotopically into the bladder lumen of syngeneic C57BL/6 mice following urothelial preconditioning, MB49-luc cells adhere to the chemically disrupted mucosal surface and proliferate into luminal masses that emit detectable photon flux as early as five to seven days post-implantation. This optical traceability eliminates the ambiguity of palpation-based staging and enables non-invasive, repeated measurement of tumor burden across the entire therapeutic window.

Fig 1. MB49-luc in-situ model experimental design. (II, Y. Maurice Morillon, et al., 2019)

Beyond simple tumor sizing, the luciferase reporter empowers sophisticated preclinical interrogations: spatial mapping of metastatic seeding to draining lymph nodes or distant organs, kinetic profiling of immune-mediated tumor regression following checkpoint blockade, and real-time visualization of intravesical vector distribution after gene-therapy delivery. The model's myeloid-suppressive microenvironment—dominated by PMN-MDSCs and characterized by delayed PD-L1 upregulation on tumor cells—mirrors a substantial subset of human bladder carcinomas, making MB49-luc particularly suited for evaluating immunomodulatory regimens where longitudinal tumor-volume tracking is essential for discerning delayed responses from pseudo-progression.

Cell Line Information: MB49-luc

MB49-luc retains the urothelial origin and aggressive growth kinetics of its parental MB49 line while adding a quantifiable optical reporter. The table below details its genetic construction, culture requirements, and imaging-compatible properties for preclinical bladder cancer research.

Our Services

Alfa Cytology constructs and manages MB49-luc orthotopic cohorts with an integrated imaging infrastructure that spans from luciferase-expression validation and in vitro signal titration to standardized D-luciferin dosing, calibrated IVIS acquisition parameters, and photon-flux data normalization. Our preclinical team tailors every imaging schedule, endpoint matrix, and tissue-harvesting protocol to your compound's mechanism of action, delivering quantifiable, audit-ready datasets that bridge in vivo tumor dynamics with ex vivo molecular characterization.

Workflow of MB49-luc Orthotopic Mouse Model Construction

Building a reliable MB49-luc orthotopic model requires seamless integration of surgical cell delivery, optical reporter integrity assurance, and standardized bioluminescence acquisition. The workflow below outlines the critical stages from cell qualification through longitudinal imaging to terminal validation.

1. Luciferase Expression Validation and Cell Preparation: MB49-luc cells are expanded under selection pressure to maintain reporter stability. Prior to implantation, an in vitro luciferase assay is performed: cells are incubated with D-luciferin substrate and imaged to confirm signal intensity and uniformity across the population. Only cultures exhibiting homogeneous, high-level bioluminescence and >85% viability (trypan blue exclusion) are advanced to the implantation stage. Cells are washed three times in serum-free DMEM and resuspended at 2×10⁶ cells/mL on ice.
2. Animal Preparation and Anesthesia: Female C57BL/6 mice, 6–10 weeks old, are housed under SPF conditions with a minimum one-week acclimation. On the procedure day, general anesthesia is induced via intraperitoneal ketamine/medetomidine (75 mg/kg and 1 mg/kg, respectively). Depth of anesthesia is verified by absence of toe-pinch reflex. Ophthalmic lubricant is applied, and the mouse is positioned supine on a thermostatically controlled surgical platform with hind limbs secured in gentle abduction.
3. Urothelial Preconditioning: A sterile 24-gauge IV catheter is advanced transurethrally into the bladder under a dissecting microscope. Residual urine is evacuated by gentle suprapubic pressure. The urothelial barrier is disrupted using either 50 µL poly-L-lysine (instilled at 10 µL per 20 seconds, retained for 20 minutes) or 100 µL of 22% ethanol (retained for 15 minutes). The preconditioning agent is fully aspirated before cell instillation to prevent cytotoxic interference with tumor engraftment.
4. Intravescial MB49-luc Instillation: The validated cell suspension—typically 5×10⁴ to 1×10⁵ cells in 50 µL serum-free medium—is delivered through the indwelling catheter at a controlled rate of 10 µL per 20 seconds. Slow infusion minimizes vesicoureteral reflux and prevents upper-urinary-tract seeding. The catheter is clamped or sealed, and the inoculum is retained within the bladder lumen for 60 minutes to maximize mucosal adhesion.
5. Post-Instillation Recovery and Initial Signal Baseline: Following the retention period, the catheter is withdrawn and the bladder is emptied by gentle abdominal compression. Mice are revived with atipamezole reversal and returned to warmed recovery cages. Daily health monitoring (body weight, hydration, posture, hematuria) is conducted for 72 hours. At 24–48 hours post-implantation, a baseline bioluminescence image may be acquired to confirm successful cell seeding, although robust signal typically emerges by day 5–7.
6. Longitudinal Bioluminescence Imaging Protocol: Tumor growth is monitored via serial IVIS imaging performed twice weekly during the first three weeks. Mice receive intraperitoneal D-luciferin (150 µg/g body weight) and are imaged under continuous anesthesia 10–15 minutes post-injection. Acquisition parameters (exposure time, binning, f/stop) are held constant across all sessions to ensure comparability. Regions of interest (ROIs) are drawn over the bladder area, and total photon flux (photons/second) is quantified for each animal. Signal trends are plotted as fold-change over baseline.
7. Endpoint Bioluminescence and Tissue Harvest: At study termination—defined by humane endpoint criteria or protocol-mandated timepoints—a final whole-body bioluminescence image is acquired to document metastatic dissemination. Mice are then euthanized, and the bladder is excised, weighed, and photographed. Tissues are partitioned for downstream analysis: formalin-fixed paraffin-embedded (FFPE) sections for H&E and immunohistochemistry, snap-frozen samples for RNA/DNA/protein extraction, and single-cell suspensions for flow-cytometric immune profiling. Ex vivo luciferase assays on tissue homogenates can corroborate in vivo imaging data.

Fig 2. MB49-luc Orthotopic Mouse Model construction workflow.

Case Study-MB49-luc Orthotopic Mouse Model Development

In a preclinical program designed to evaluate a novel intravesical oncolytic adenovirus platform, Alfa Cytology established an orthotopic MB49-luc cohort to enable real-time quantification of both tumor burden and vector biodistribution. Following standardized bladder preconditioning and cell instillation, bioluminescence imaging confirmed uniform tumor engraftment across all animals by day 7, with photon flux increasing logarithmically through day 18. The study architecture included an intravesical BCG reference arm, a low-dose viral vector arm, and a combination arm pairing the vector with systemic anti-PD-1 blockade. Serial imaging revealed differential growth kinetics between monotherapy and combination groups as early as day 12, while terminal flow-cytometric analysis of bladder-infiltrating leukocytes demonstrated treatment-dependent shifts in PMN-MDSC abundance and CD8+ T-cell activation status. These imaging-anchored datasets provided the sponsor with pharmacodynamic evidence supporting advancement to subsequent IND-enabling toxicology studies.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your MB49-luc orthotopic partner means gaining access to a preclinical infrastructure where optical traceability, surgical precision, and analytical depth converge to de-risk your therapeutic development pathway.

• In-house luciferase-expression QC and signal-stability monitoring ensure that every implanted cohort begins with validated, high-fidelity reporter cells.
• Calibrated IVIS imaging protocols with locked acquisition parameters enable statistically robust, longitudinal photon-flux comparisons across treatment arms and timepoints.
• The immunocompetent C57BL/6 background preserves native tumor-immune interactions, supporting reliable evaluation of checkpoint inhibitors, myeloid-targeting agents, and combination regimens.
• Customizable imaging frequencies and dual-readout designs (bioluminescence plus ultrasound or urinary biomarkers) accommodate compounds with varying mechanisms and onset kinetics.
• Terminal tissue-banking services—including FFPE, frozen-section, and single-cell suspension archives—allow retrospective molecular validation of imaging-derived hypotheses.
• All procedures are executed under IACUC-approved protocols within SPF barrier facilities, with full documentation chains and GLP-compatible data packages available upon request.

Contact Us

If your bladder cancer research program demands a quantifiable, immunocompetent orthotopic model with real-time bioluminescence readouts, reach out to Alfa Cytology to discuss your specific objectives. Our scientific team will collaborate with you to design a tailored MB49-luc imaging study, define acquisition schedules aligned with your compound profile, and provide a comprehensive project proposal. Contact us today to transform your preclinical discovery data into actionable translational insights.

For research use only. Not intended for any clinical use.